Chinese Phase 2b RCT of telitacicept (TACI-Fc fusion protein inhibits both BAFF & APRIL) 3 doses vs PBO in 249 active SLE pts. Wk 48 SRI-4 response favored TELI (76% 240 mg, 68% 160 mg, 71% 80 mg vs 34% w/ PBO (all p<0.001) https://t.co/fz4W1le4Db https://t.co/0mTC4gQcdr
Links:
Telitacicept in patients with active systemic lupus erythematosus: results of a…
https://bit.ly/41LOn45
03-01-2024